Cyclobenzaprine-d3 (hydrochloride) (CRM)
(Synonyms: 盐酸环苯扎林-D3,MK130-d3 hydrochloride) 目录号 : GC48766
A Certified Reference Material
Cas No.:1184983-42-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyclobenzaprine-d3 (hydrochloride) (CRM) contains three deuterium atoms at the terminal methyl group. It is intended for use as an internal standard for the quantification of cyclobenzaprine by GC- or LC-mass spectrometry. Cyclobenzaprine is a skeletal muscle relaxant that also has sedative properties.1,2,3 It has been shown to antagonize muscarinic receptors (Kis = 25, 60, and 6 nM for M1, M2, and M3, respectively), serotonin 5-
1.Trivedi, R.K., and Patel, M.C.Development of a stability-indicating RP-UPLC method for rapid determination of metaxalone and its degradation products in solid oral dosage formSci.Pharm.80(2)353-366(2012) 2.Chou, R., Peterson, K., and Helfand, M.Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic reviewJ. Pain Symptom Manage.28(2)140-175(2004) 3.See, S., and Ginzburg, R.Choosing a skeletal muscle relaxantAmerican Family Physician78(3)365-370(2008) 4.Gregori-PuigjanÉ, E., Setola, V., Hert, J., et al.Identifying mechanism-of-action targets for drugs and probesProc. Natl. Acad. Sci. USA109(28)11178-11183(2012) 5.Honda, M., Nishida, T., and Ono, H.Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT2 receptorsEuropean Journal of Pharmacology458(1-2)91-99(2003) 6.Lounkine, E., Keiser, M.J., Whitebread, S., et al.Large scale prediction and testing of drug activity on side-effect targetsNature486(7403)361-367(2012)
| Cas No. | 1184983-42-3 | SDF | |
| 别名 | 盐酸环苯扎林-D3,MK130-d3 hydrochloride | ||
| Canonical SMILES | CN(C([2H])([2H])[2H])CC/C=C1C2=C(C=CC=C2)C=CC3=C/1C=CC=C3.Cl | ||
| 分子式 | C20H18D3N•HCl | 分子量 | 314.9 |
| 溶解度 | 储存条件 | -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1756 mL | 15.8781 mL | 31.7561 mL |
| 5 mM | 0.6351 mL | 3.1756 mL | 6.3512 mL |
| 10 mM | 0.3176 mL | 1.5878 mL | 3.1756 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。